G. Massimini

发表

Phase I trial of 9-cis retinoic acid in adults with solid tumors.

S. Lippman, J. Kurie, W. Hong, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.

L. Dirix, M. Kaufmann, S. Jones, 2000, Clinical breast cancer.

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.

P. Lønning, N. Aaronson, M. Tubiana-Hulin, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial.

L. Dirix, M. Kaufmann, S. Jones, 2000, European journal of cancer.

Activity o f E xemestane i n M etastatic B reast C ancer After F ailure o f N onsteroidal A romatase I nhibitors: A P hase I I T rial

N. Aaronson, M. Mita, A. Polli, 2000 .

conventional therapy for the disease or resistant acute myeloid leukemia (AML) or not amenable to A phase 1 study of SU11248 in the treatment of patients with refractory

J. Cherrington, W. Berdel, O. Ottmann, 2013 .

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.

A. Johne, H. Scheible, O. von Richter, 2016, British journal of clinical pharmacology.

Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study

L. Dirix, M. Kaufmann, Stephen E. Jones, 1999 .

A multicenter, randomized, phase Ib/II trial of the oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in Asian patients with MET-positive (MET+) advanced hepatocellular carcinoma (HCC) and Child-Pugh Class A liver function.

Li-an Xu, A. Cheng, H. Lim, 2014 .

Lipid and coagulation profile in postmenopausal women with early breast cancer at low risk treated with exemestane: A randomized, placebo-controlled study.

P. Lønning, L. Ottestad, J. Geisler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk.

P. Lønning, L. Ottestad, J. Geisler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma.

P. Carlini, G. Boccoli, P. Marolla, 1990, European journal of cancer.

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

R. Larson, B. Druker, F. Guilhot, 2005 .

13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix.

S. Lippman, W. Hong, J. Kavanagh, 1993, Journal of the National Cancer Institute.

Research and Drug Development in Paediatric Oncology

G. Vassal, K. Pritchard-Jones, K. Rose, 2010 .

High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.

O. Mariani, J. Bonneterre, L. Dirix, 2000, European journal of cancer.

Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study

P. Lønning, L. Fallowfield, L. Gibson, 2003, BMJ : British Medical Journal.

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

L. Dirix, M. Kaufmann, Stephen E. Jones, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

E. Raymond, C. Robert, J. Armand, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

C. Garbe, E. Espinosa, A. Schueler, 2020, Cancers.

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

Randy Allred, Hubert Serve, Wolfgang E Berdel, 2005, Blood.

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors

E. Raymond, J. Schellens, A. Italiano, 2020, Targeted Oncology.

Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.

Tillmann Krahnke, R. Larson, B. Druker, 2006, Blood.

Collagen synthesis by Duchenne myogenic clones: pathogenic implications for the disease.

V. Ionasescu, A. Sandra, G. Massimini, 1982, American journal of medical genetics.

Interferon alfa 2a in superficial bladder cancer prophylaxis: toleration and long-term follow-up. A phase I-II study.

G. Massimini, D. Criscuolo, R. Bartoletti, 1991, Anticancer research.

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

J. Melo, G. McArthur, J. Goldman, 2007, Blood.

Long term results of an adjuvant therapy with low doses IFN-??2A in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases: 113

C. Chastang, L. Thill, B. Dréno, 1997 .

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.

P. Lønning, B. Erikstein, J. Geisler, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial

E. Raymond, J. Schellens, A. Italiano, 2020, Targeted Oncology.

Hormonal therapy in breast cancer and predominant visceral disease: effectiveness of the new oral aromatase inactivator, Aromasin® (exemestane), in advanced breast cancer patients having progressed on antiestrogens

M. Kaufmann, Stephen E. Jones, A. Polli, 1999 .

Activity of exemestane, an irreversible, oral, aromatase inhibitor in metastatic postrnenopausal breast cancer patients (MBC) failing tamoxifen (TAM)

O. Mariani, J. Bonneterre, L. Dirix, 1998 .

Estrogens and bone metabolism in postmenopausal women with early breast cancer at low risk treated with exemestane: a randomized placebo-controlled study

P. Lønning, L. Ottestad, J. Geisler, 2004 .

Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors.

S. Lippman, E. Eisenhauer, W. Hong, 1994, Leukemia.

Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.

G. Batist, T. Shore, F. Porzsolt, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival

N. Girard, R. Schilsky, R. Berger, 2021, npj Precision Oncology.

Phase II Study of Interferon α‐2a and Dacarbazine in Advanced Melanoma

N. Cascinelli, B. Giannotti, G. Zumiani, 1990 .

Estrogens and bone metabolism in postmenopausal women with early breast cancer at low risk treated with exemestane: a randomized placebo-controlled study.

P. Lønning, L. Ottestad, J. Geisler, 2004, Journal of Clinical Oncology.

A retrospective analysis of health care costs for bone fractures in women with early‐stage breast carcinoma

O. Johnell, R. Willke, A. Redaelli, 2004, Cancer.

Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate.

E. Seregni, E. Bombardieri, R. Giovanazzi, 2003, Anticancer research.

A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.

P. Lønning, L. Fallowfield, L. Gibson, 2004 .

Estrogen suppression of 8-week treatment with exemestane combined with triptorelin versus triptorelin alone in healthy premenopausal women.

P. Buchan, E. di Salle, N. Pirotta, 2004, Journal of Clinical Oncology.

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

H. Döhner, J. Cherrington, D. Hossfeld, 2005, Blood.

Procede combine de traitement de troubles hormonodependants

G. Massimini, G. Piscitelli, D. Purandare, 2002 .